Goldman Sachs’s BioXcel Therapeutics BTAI Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-24,794
| Closed | -$50.3K | – | 5146 |
|
|
2025
Q1 | $50.3K | Buy |
+24,794
| New | +$50.3K | ﹤0.01% | 4912 |
|
|
2024
Q3 | – | Sell |
-98,967
| Closed | -$127K | – | 4845 |
|
|
2024
Q2 | $127K | Buy |
98,967
+76,197
| +335% | +$97.5K | ﹤0.01% | 4469 |
|
|
2024
Q1 | $64.2K | Buy |
22,770
+3,570
| +19% | +$10.1K | ﹤0.01% | 4511 |
|
|
2023
Q4 | $56.6K | Sell |
19,200
-113,674
| -86% | -$335K | ﹤0.01% | 4526 |
|
|
2023
Q3 | $336K | Sell |
132,874
-11,172
| -8% | -$28.3K | ﹤0.01% | 4057 |
|
|
2023
Q2 | $959K | Sell |
144,046
-19,604
| -12% | -$131K | ﹤0.01% | 3631 |
|
|
2023
Q1 | $3.05M | Buy |
163,650
+110,226
| +206% | +$2.06M | ﹤0.01% | 2916 |
|
|
2022
Q4 | $1.15M | Sell |
53,424
-40,085
| -43% | -$861K | ﹤0.01% | 3620 |
|
|
2022
Q3 | $1.11M | Buy |
93,509
+20,835
| +29% | +$246K | ﹤0.01% | 3756 |
|
|
2022
Q2 | $959K | Buy |
72,674
+3,926
| +6% | +$51.8K | ﹤0.01% | 3971 |
|
|
2022
Q1 | $1.44M | Buy |
68,748
+19,014
| +38% | +$397K | ﹤0.01% | 3844 |
|
|
2021
Q4 | $1.01M | Buy |
49,734
+13,765
| +38% | +$280K | ﹤0.01% | 4012 |
|
|
2021
Q3 | $1.09M | Sell |
35,969
-141,621
| -80% | -$4.3M | ﹤0.01% | 3911 |
|
|
2021
Q2 | $5.16M | Buy |
177,590
+51,125
| +40% | +$1.49M | ﹤0.01% | 2759 |
|
|
2021
Q1 | $5.46M | Sell |
126,465
-98,178
| -44% | -$4.24M | ﹤0.01% | 2605 |
|
|
2020
Q4 | $10.4M | Buy |
224,643
+97,032
| +76% | +$4.48M | ﹤0.01% | 2033 |
|
|
2020
Q3 | $5.53M | Buy |
127,611
+27,632
| +28% | +$1.2M | ﹤0.01% | 2317 |
|
|
2020
Q2 | $5.3M | Buy |
99,979
+50,068
| +100% | +$2.65M | ﹤0.01% | 2310 |
|
|
2020
Q1 | $1.12M | Buy |
+49,911
| New | +$1.12M | ﹤0.01% | 3055 |
|
|
2018
Q3 | – | Sell |
-10,620
| Closed | -$98K | – | 4114 |
|
|
2018
Q2 | $98K | Sell |
10,620
-17,260
| -62% | -$159K | ﹤0.01% | 4012 |
|
|
2018
Q1 | $285K | Buy |
+27,880
| New | +$285K | ﹤0.01% | 3720 |
|